Latest Media Releases

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Immutep completes institutional pro-rata offer & placement (ASX:IMM)

Immutep Limited ACN 009 237 889 (ASX: IMM) (Immutep or the Company) is pleased to announce the successful completion of its institutional placement (Placement) and the institutional component (Insti...read more

Immutep announces Ph 3 clinical trial collaboration with MSD (ASX:IMM)

-- Phase III collaboration will evaluate efti in combination with KEYTRUDA, MSD’s anti-PD-1 therapy, and standard chemotherapy in first-line non-small cell lung cancer (1L NSCLC) -- TACTI-004...read more

Immutep Capital Raising Presentation (ASX:IMM)

To view the presentation, download the attached PDF.

Immutep - A$100 million fully underwritten equity raising (ASX:IMM)

Immutep Limited ACN 009 237 889 (ASX: IMM) (Immutep or Company) is pleased to announce that it has launched a fully underwritten approximately $100 million equity raising (Offer) through a pro rata ...read more

Immutep - AIPAC-003 safety lead-in data presented at ESMO Breast 2024 (ASX:IMM)

Confirmed complete response in a patient with metastatic breast cancer refractory to several lines of therapy achieved during combination treatment with 90mg efti and paclitaxel ...read more

Immutep - Positive initial data in phase 2 Soft Tissue Sarcoma trial (ASX:IMM)

Novel triple combination of efti with radiotherapy and anti-PD-1 therapy is well tolerated and has led to encouraging initial efficacy data in EFTISARC-NEO Phase II trial Four ...read more

Immutep Quarterly Activities Report and Appendix 4C (ASX:IMM)

First clinical data from the safety lead-in of AIPAC-003 in metastatic breast cancer shows 90mg dosing of efti safe and well tolerated: 50% overall response rate, including one patie...read more

Immutep - Positive preliminary topline results from TACTI-003 Cohort B (ASX:IMM)

Data from efti in combination with KEYTRUDA® in first line head and neck squamous cell carcinoma patients who do not express PD-L1 (TACTI-003, Cohort B) shows a preliminary 26.9%...read more

Immutep - CHDR to conduct first-in-human phase 1 trial of IMP761 (ASX:IMM)

-- Centre for Human Drug Research (CHDR) will conduct Phase I trial to evaluate IMP761, a first-in-class LAG-3 agonist antibody designed to restore balance to the immune system and address the under...read more

Immutep - Positive Feedback received from Spanish Medicines Agency (ASX:IMM)

SYDNEY, AUSTRALIA – April 17, 2024 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel...read more

Immutep - First Clinical Data announced from 90mg Dosing of Efti (ASX:IMM)

-- Data from the safety lead-in of the AIPAC-003 trial shows 90mg efti in combination with paclitaxel is safe and well tolerated -- Encouraging initial efficacy in six metastatic breast cancer pati...read more

Immutep - Half Yearly Report and Accounts (ASX:IMM)

To view the report, download the attached PDF.

Immutep - Appointment of Non-Executive Director (ASX:IMM)

SYDNEY, AUSTRALIA – 14 February 2024 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing nov...read more

Immutep Quarterly Activities Report and Appendix 4C (ASX:IMM)

-- Excellent clinical data reported from TACTI-002 Phase II trial, including median Overall Survival of 35.5 months in first line non-small cell lung cancer (1L NSCLC) patients expressing PD-L1 (TPS...read more

Immutep Corporate Presentation (ASX:IMM)

To view the presentation, download the attached PDF.

Viewing: 31 - 45 of 200 Previous | Next